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The cellular transformation of normal functional cells to neoplastic ones implies 
alterations in the cellular metabolism and mitochondrial function in order to provide the 
bioenergetics and growth requirements for tumour growth progression. Currently, the 
mitochondrial physiology and dynamic shift during pituitary tumour development are not well 
understood. Pituitary tumors present endocrine neoplastic benign growth which, in previous 
reports, we had shown that in addition to increased proliferation, these tumours were also 
characterized by cellular senescence signs with no indication of apoptosis. Here, we show clear 
evidence of oxidative stress in pituitary cells, accompanied by bigger and round mitochondria 
during tumour development, associated with augmented biogenesis and an increased fusion 
process. An activation of the Nrf2 stress response pathway together with the attenuation of the 
oxidative damage signs occurring during tumour development were also observed which will 
probably provide survival advantages to the pituitary cells. These neoplasms also presented a 
progressive increase in lactate production, suggesting a metabolic shift towards glycolysis 
metabolism. These findings might imply an oxidative stress state that could impact on the 
pathogenesis of pituitary tumours. These data may also reflect that pituitary cells can modulate 
their metabolism to adapt to different energy requirements and signaling events in a 
pathophysiological situation to obtain protection from damage and enhance their survival 
chances. Thus, we suggest that mitochondria function, oxidative stress or damage might play a 

















 Bigger mitochondria with increased fusion evidence were seen in pituitary tumours.  
 Pituitary tumours showed increased ROS levels and signs of oxidative damage. 
 The Nrf2 pathway was activated in pituitary tumours as an antioxidant response. 
 Glycolysis may favour cell growth and survival in experimental pituitary tumours. 
Abbreviations 
8OH-G: 8-hydroxyguanine, CK: Creatine kinase, 2 , CS: citrate synthase, DNMT1-3A-3B: DNA 
methyltransferase 1, 3A, 3B, DRP1: dynamin-related protein 1, p-DRP1: dynamin-phosphorylated 
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related protein 1, ETC: electron transport chain, HO-1: heme oxygenase, MFF1 and MFN2: 
mitofusin 1 and mitofusin 2, MMP: mitochondrial membrane potential, NRF1 and NRF2: nuclear 
respiratory factor 1 and nuclear respiratory factor 2, Nrf2: nuclear factor erythroid- related factor 
2, p-Nrf2: phosphorilated nuclear factor erythroid- related factor 2, OGG1: 8-Oxoguanine DNA 
glycosylase/AP lyase 1, OPA1: Optic atrophy 1 gene protein, OXPHOS: oxidative phosphorylation, 
PCC: protein carbonyl group content, ROS: reactive oxygen species, TFAM: transcription factor A 
mitochondrial, γ H2AX: phosphorilated histone H2AX, TET1-3: ten-eleven translocation 1-3. 
 
Introduction 
Pituitary tumours are trophically stable benign neoplasms that typically show relatively 
little change in size over many years and may be the main basis of endocrine dysfunction. The 
current understanding of the molecular pathogenesis of pituitary adenomas is considered as a 
multifaceted process that involves the participation of both extrinsic and intrinsic factors. 
Recently, a substantial improvement has been made in the recognition of the mechanisms and 
agents implicated at the beginning and during the evolution of pituitary tumours. These tumours 
do not present the typical oncogene mutations often found in nonendocrine neoplasms and the 
particular aspects that contribute to the initiation and promotion of their development have 
already been characterized [1, 2]. These factors, such as cell cycle deregulation, growth factor 
overexpression, hormonal overstimulation, epigenetically silenced tumour suppressor genes, 
oncogene overexpression, defective signalling pathways and an altered intrapituitary 
microenvironment, act as mitogenic stimuli that can lead to sustained tumour growth [1, 3-8]. 
However, an alternative approach based on data derived from the mitochondrial role during 
pituitary tumorigenesis has not yet been fully considered. Mitochondria influence cell function and 
adaptation by dynamic fluctuations, and due to their participation in numerous critical outgrowths 
of cell function, they are important contributors to intracellular signalling and can affect 
homeostasis in several interconnected manners. Mitochondrial dysfunction can directly provoke 
several of the adverse cellular outcomes related to chronic stress, including oxidative stress, 
inflammation, telomere shortening, epigenetic dysregulation, altered gene expression and cellular 
senescence [9]. In addition, recent advances in molecular biology have provided innovative ways 
to interpret the role of the cellular metabolism and mitochondrial function in the development 
and progression of tumours.  
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Cellular transformation of normal and functional cells to neoplastic ones implies 
alterations in the cellular metabolism and mitochondrial function in order to provide the 
bioenergetics and growth requirements for tumour growth progression [10, 11]. Thus, without 
metabolic transformation, the neoplastic cell will not be able to attain an unregulated growth 
potential. Therefore, it is critical to establish the role of the mitochondria during pituitary 
tumorigenesis. 
The ultrastructure, composition and function of mitochondria diverge significantly from 
tumoral to normal cells. For instance, an increased rate of glycolysis (Warburg effect) has been 
described as an inherent property of tumoral cells [12]. Also, rapidly growing tumours may show 
fewer and smaller mitochondria with scarcer cristae than those from slowly growing tumours, 
which tend to present characteristics resembling normal cells [11]. Additional differences between 
the mitochondria of normal vs. transformed cells have similarly been described with regard to 
preference for substrates, mitochondrial membrane potential, protein synthesis, organelle 
turnover and reactive oxygen species (ROS) production [10]. 
Mitochondria are key components of the stress response owing their role in energy 
production and their ability to generate signals that promote cellular adaptation [13]. For example, 
mitochondrial biogenesis can modify the number of organelles to adapt the total cellular energy 
capacity. Also, mitochondrial network can undergo fission or fusion as a response that could 
promote survival in the context of cellular stress signals.  
Metabolic processes may result in an increase in the ROS production [14]. When 
production of ROS exceeds the cell antioxidant capacity, oxidative stress and oxidative damage to 
biomolecules (proteins, DNA and RNA) may take place, and this may have a causative role in the 
progression of tumorigenesis [15]. Adaptive responses to environmental and endogenous stresses 
involve the activation of the Keap1-nuclear factor erythroid-related factor 2 (Nrf2) signalling 
pathway, which regulates the expression of an extended group of cytoprotective genes [16]. 
Few attempts to elucidate mitochondrial health in pituitary tumours have been made [18-
22], with currently little being known about mitochondrial behaviour during endocrine tumour 
development. The pituitary gland mostly develops benign proliferative injuries with the 
coexistence of mitotic events together with cellular senescence arrested cells and practically null 
apoptotic rates [17-26]. As a dynamic and plastic tissue the pituitary gland constantly adapts 
hormonal and metabolic responses to the changing environments [27]. Thus, we have interpreted 
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the existence of a pituitary senescent barrier as being a failsafe mechanism that may allow the 
survival of the gland, complementing its relevant role in organism homeostasis. Here, we focused 
our attention on how the mitochondrial fitness outcome supports these tumoral features, 
implying an adaptation of the mitochondrial structure and dynamics, energy production 
mechanisms and detoxification processes. As little is known about mitochondria behaviour and 
energy metabolism in pituitary tumours [28-31], in the present work we analysed a wide range of 
parameters, which were taken into account during the development of in vivo experimental 
pituitary tumours. This helped us to conceive an overview of the progressive mitochondrial 
switches needed for the survival of pituitary cells in order to cope with neoplastic injury. 
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2. Materials and methods 
2.1 Animals and experimental models 
Three-month-old Wistar strain male rats were maintained at controlled temperature (21±3 °C) and 
lighting conditions (14 h light: 10 h darkness cycle), with free access to commercial laboratory 
chow and tap water. Taking into account that exogenous estrogen excess induces pituitary 
tumours [17, 32], intact animals were treated with estradiol benzoate (Sigma Aldrich, St. Louis, 
MO, USA) for 10, 20, 40, and 60 days (E10, E20, E40, and E60). Estrogen was implanted 
subcutaneously in slow releasing silastic brand capsules (Dow Corning, Medical grade, Midland, 
MI, USA) filled with 10 mg of estrogen crystals and sealed with silastic cement. The control group 
was implanted with empty capsules. Rats were decapitated within 10 s after being removed from 
their cage, thus avoiding any stress or external stimuli. The animals were kept in accordance with 
the Guide for the Care and Use of Laboratory Animals, published by the United States National 
Institutes of Health (1996), and the experiments were approved by the Institutional Animal Care 
Committee of the School of Medicine, National University of Córdoba. 
 
2.2 Pituitary cell dissociation 
The protocol for pituitary cell dissociation has been previously described [33]. Briefly, rat pituitary 
glands were placed in minimal essential medium, and then minced and digested with 0.4 % w/v 
trypsin at constant slow agitation at 37°C. The cell suspension was gently dispersed using flame-
rounded Pasteur pipettes. Cell viability, tested with Trypan blue exclusion, was always better than 
90%. Cell dispersions were transferred to 1.5 ml eppendorf tubes and centrifuged at 400 g for 
5min. 
 
2.3 Cellular fractionation 
The subcellular fractionation was performed as described by Mongi Bragato and coworkers (2016). 
Briefly, pituitary glands from control or estrogenized animals were homogenized in cytoplasmic 
extract buffer [10 mM Hepes pH 7.5, 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM 
NaVO4, 1 mM phenylmethanesulfonyl fluoride (PMSF), 1 μg/mL Aprotinin, 1 μg/mL Leupeptin, 1 
μg/mL pepstatin, 0.075% Nonidet P40 (NP40)], and centrifuged at 2000 xg for 5 min at 4°C to 
pellet out THE nuclei fraction. Supernatants were centrifuged at 10000 xg for 10 min at 4°C, and 
the resulting ones were used as cytoplasmic extracts. Nuclear pellets were resuspended in nuclear 
extract buffer (20 mM Tris HCl pH 8, 420 mM NaCl, 60 mM KCl, 1 mM EDTA, 1 mM NaVO4, 1mM 
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PMSF, 25% glycerol, 1 μg/mL Aprotinin, 1 μg/mL Leupeptin, 1 μg/mL pepstatin), and centrifuged at 
10000 g for 10 min at 4°C. The resulting supernatants were used as nuclear extracts. Aliquots of 
each sample were used for total protein quantification according to the Bradford method (Bio-Rad 
Protein Assay, Bio-Rad). 
 
2.4 Western blotting analysis 
Protein (40ug) from the subcellular fractionation was separated by SDS-PAGE and transferred to a 
nitrocellulose membrane and blocking was performed using bovine serum albumin (BSA) (Sigma 
Aldrich) 5% in TBS 1X/tween-20 0.1 %. To estimate the corresponding molecular weights, the 
Precision Plus Protein Standards molecular weight marker was used (Bio-Rad). Membranes were 
incubated overnight at 4°C with the corresponding primary antibody: goat polyclonal anti-OPA-1 
(1/200), rabbit polyclonal anti-MFN-2 (1/250), rabbit polyclonal anti-phosphorilated-DRP-1 serine 
637 (1/500; Cell Signaling), mouse monoclonal anti-8-hydroxyguanine (8OH-G) (1/100), mouse 
polyclonal anti- phosphorilated Histone H2AX (p-H2AX) (1/2000, Cell Signaling), rabbit 
monoclonal anti-Nrf-2 (1/500, Abcam) rabbit monoclonal anti-phosphorilated Nrf-2 serine 637 (p-
Nrf-2) (1:500, Abcam), mouse monoclonal anti- tubulin (1:2500; Sigma Aldrich), rabbit anti-Lamin 
B (Lam B) (1/500; Cell Signaling), rabbit polyclonal anti-Heme Oxygenase 1 (HO-1) (1/200, Santa 
Cruz Biotecnology), anti-DNA methyltransferase-1 (DNMT-1) (Cell Signaling, 1/1000) or anti-β-
Actin (1/4000; Sigma-Aldrich). After washing, blots were incubated with a peroxidase-conjugated 
(HRP) goat anti-rabbit (1/5000; BioRad), goat anti-mouse (1/3000; Jackson Laboratories) or mouse 
anti-goat (1/1000, Santa Cruz Biotechnology), diluted in blocking buffer, rinsed in TBS 1X/Tween 
0.1 %, and revealed with an ECL detection system (Amersham Biosciences). Emitted light was 
captured on Hyperfilm (Amersham Pharmacia Biotech). The -tubulin, β-actin or Lam B antibodies 
were used as loading controls, and values were expressed as the percentage of the control. Semi-
quantitative signals were derived from densitometric analysis using the ImageJ software (1.51o 
Wayner Rasband National Institute of Health, USA). 
 
2.5 Transmission electron microscopy (TEM) 
With the objective of evaluating the mitochondrial ultrastructural features of pituitary cells, 
normal and estrogen-induced tumoral pituitaries were fixed in a mixture of 4 % formaldehyde and 
2 % glutaraldehyde in 0.1 M cacodylate buffer, before being treated with 1% OsO4 as previously 
described [34]. Then, the Araldite-embedded pituitary thin sections were cut with a diamond knife 
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on a JEOL JUM-7 ultramicrotome (Nikon, Tokyo, Japan) and examined using a Zeiss Leo 906 E 
electron microscope equipped with the digital camera Megaview III (Oberkochen, Germany). For 
quantitative analysis of the mitochondrial number and morphology, three glands from each 
experimental condition were used, and fifty random micrographs of the same slide region were 
acquired at a 10000X magnification (50 micrograph/experimental condition/per animal) and 
analysed using Image J software (1.51o Wayner Rasband National Institute of Health, USA), to 
determine the mitochondria number/field, area, circularity (4π x [area/(perimeter)2) and 
elongation (mayor axis/minor axis) [35-37]. 
 
2.6 Immunohistochemistry 
Paraffin-embedded pituitary glands were processed by immunohistochemistry for 8-OHG as 
described previously [17]. Briefly, an antigen retrieval method using a hot antigen unmasking 
solution was performed (0.01 M citrate buffer; pH 6), and in order to inhibit endogenous 
peroxidase, sections were treated with 3 % v/v hydrogen peroxide in methanol for 15 min. 
Subsequently, these sections were incubated for 30 min in 10 % v/v normal serum (Sigma–Aldrich) 
to block nonspecific binding, followed by overnight incubation with monoclonal anti-8-OHG 
antibody (1/200). Next, sections were incubated with biotinylated secondary antibody (1/300; 
Amersham; Buckinghamshire, England) and ABC complex (Vector Laboratories, Burlingame, CA, 
USA) with 3,3’-diaminobenzidine tetrahydrochloride being used as a chromogenic substrate 
(Sigma Aldrich). Finally, sections were rinsed in running water and counterstained with 
hematoxylin (Sigma Aldrich). Controls were performed by applying the same protocol, but 
omitting primary antibodies. Slides from three animals of each experimental condition were 
photographed in randomly chosen fields at 400 X. 
 
2.7 Immunofluorescence 
To assess DMNT 1 localization, additional sets of slides from different experimental conditions 
were processed for fluorescence microscopy. LR White-embedded pituitary glands (London Resin 
Corporation, Berkshire, UK) were processed as described elsewhere [34]. Briefly, thin sections 
were cut with a diamond knife on a Porter-Blum MT2 and JEOL JUM-7 ultramicrotome and then 
incubated for 2 h in glicine (100 mM/Buffer Tris pH 7.4) in order to reduce auto-fluorescence 
according to Baschong, Suetterlin and Laeng [38]. After the pituitary sections had been incubated 
with anti-DMNT1 (1/100 Cell signalling) overnight, these slices were washed, and further 
incubated with Alexa 594 anti-rabbit secondary antibodies (1/2000; Invitrogen; Carlsbad, USA) for 
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1 hour. Images were then obtained using the confocal microscope Axioplan (Carl Zeiss, Jena, 
Alemania) and collected with a 60 X objective. The analysis of these images was carried out using 
ImageJ software (1.51o Wayner Rasband National Institute of Health, USA). 
 
2.8 Sequential RNA and DNA co-extraction 
Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer's instructions. Sequential DNA co-extraction was performed from the interphase 
and organic layer obtained after centrifugation. Then, the genomic DNA (gDNA) was precipitated 
with 100 % ethanol and the pellet was washed with sodium citrate/ethanol buffer (0.1 M sodium 
citrate in 10% ethanol, pH 8.5) and 70 % ethanol and dissolved in 50 μl of NaOH 8 mM, with the 
RNA and gDNA integrity and concentration being measured using a NanoDrop spectrophotometer 
(Thermo Scientific, Uniscience, USA). 
 
2.9 Semiquantitative RT-PCR analysis 
Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer's instructions. Thereafter, 1 μg of total RNA was used as a template for reverse 
transcription using EpiScript™ Reverse Transcriptase (Epicentre, Madison, WI) with random 
hexamer primers (Thermo Fisher Scientific, Waltham, MA USA). The cDNA obtained was subjected 
to PCR amplification using GoTaq DNA Polymerase (Promega, Madison, WI), and following this,  
PCR protocols were performed according to the manufacturer’s instructions. PCR amplification 
was performed in 10 μl using a specific primers sets (Table 1), and the PCR amplified products 
were visualized by electrophoresis onto 2% agarose gels by GelSampleRedTM (Biotium) staining, 
whit the band densitometric analysis being carried out using ImageJ software. 
 
2.10 Global DNA methylation analyses whit with MspI/HpaII endonucleases 
Global DNA methylation was evaluated by restriction endonuclease digestion of 1000 μg of 
genomic DNA digested with 10 μl of reaction mixture of restriction endonucleases MspI or HpaII 
(10 U; Fermentas, St. Leon-Rot, Germany) in separate reactions in appropriate buffers and 
digested at 37 °C for 16 h. Both endonucleases have the same restriction site (CCGG), although 
HpaII is also sensitive to DNA methylation. The reaction products were resolved by electrophoresis 
onto 0.8 % agarose gel. Band densitometric analysis was carried out using ImageJ software, and 
the percentage of methylation was calculated using the formula: global DNA methylation content 
= (HpaII-MspI) x 100/ undigested genomic DNA [39]. 
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2.11 TP53 promoter methylation analysis by methylation-sensitive restriction enzymes  
To evaluate the TP53 promoter methylation status, firstly gDNA samples were digested with 
methylation sensitive HpaII restriction endonuclease (New England Biolabs, Ipswich, MA, USA), 
which can recognize unmethylated CCGG motifs, at 37 °C for 4 h in a 10 µl reaction volume. This 
was followed by inactivation at 65°C for 20min. Afterwards, the digested gDNA samples were 
amplified with primers (Table 1) flanking the CCGG motifs in the promoter region of the P53 gene. 
The PCR amplified products were analysed by electrophoresis onto 2 % agarose gel with 
undigested gDNA with amplification control, and band densitometric analysis was obtained using 
ImageJ software. The percentage of promoter methylation was calculated considering that the 
value of the undigested gDNA sample quantification represented the total amplified DNA template 
(100 % of the initial template copies were amplified) and, tha the value of HpaII-digested samples 
represented the total amplified DNA. The percentage of methylation was calculated using the 
formula: promoter methylation content = (HpaII) x 100/ undigested gDNA [40]. 
 
2.12 Measurement of creatine kinase activity 
Creatine kinase (CK) activity was determined in pituitary homogenates by measuring creatine 
formation by the colorimetric method [41] using a commercial kit of CK (Doles, Goiania, Brazil) 
according to the manufacturer's instructions. The results from pituitary homogenates of 3 animals 
per experimental group were expressed as µmol of creatine/min/mg protein. 
 
2.13 Protein carbonyl content 
The protein oxidative damage was measured by determining the of protein carbonyl group 
content (PCC), based on the reaction with dinitrophenylhydrazine (DNPH) [42]. Normal and 
tumoral pituitary gland supernatants were treated with 4 mmol DNPH dissolved in 2.5 N HCl or 
with 2.5 N HCl (blank control) and left in the dark for 1 h. Samples were then precipitated with 20 
% TCA and centrifuged for 5 min at 10000 xg. Next, pellets were washed with 1 ml ethanol: ethyl 
acetate (1:1 v/v) and re-dissolved in 6 M guanidine prepared in 2.5 N HCl, and samples were 
incubated at 37 °C for 5 min to assure complete dissolution of the pellet, with the resulting sample 
being examined at 360 nm. Differences between DNPH-treated and HCl-treated samples were 
used to estimate the PCC. Results were calculated as pmol of carbonyls groups/mg protein, using 





2.14 Mitochondrial membrane potentials and ROS production 
JC-1 (MitoProbe™ JC-1 Assay Kit for Flow Cytometry-M34152) is a lipophilic cation, which 
selectively accumulates, either within the mitochondrial matrix as a green (527 nm) fluorescent 
monomer at depolarized membrane potentials, or as J-aggregates with orange-red (590 nm) 
fluorescence at hyperpolarized membrane potentials [43]. DCFH-DA (Molecular Probes™ Reactive 
Oxygen Species Detection Reagents-mp36103) is a cell-permeant dye that once inside the cell is 
cleaved by intracellular esterase into its non-fluorescent form DCFH. This probe, which is no longer 
membrane permeant, may be further oxidized by ROS to its fluorescent form DCF [44]. Here, 
fluorescence emission from DCF (green) was detected at a wavelength of 530 nm.  
In order to determine the mitochondrial membrane potential and ROS production, dispersed 
pituitary cells from normal and estrogen-treated animals were incubated with 500 µl of DMEM 
supplemented with 10 % foetal bovine serum (150000 cells / treatment). Then, 0.5 µl of JC-1 
(Stock solution 2 µM) or 2.5 µl DCFH-DA (Stock solution 10uM) were added to each sample and 
incubated at 37 °C for 30 min under 5 % CO2, after which, pituitary cells were washed twice at 
37°C with filtrate phosphate buffer saline (PBS), resuspended in a 100 µl final volume and analysed 
by flow cytometry (BD FACS Canto II). The accumulation of JC-1 in pituitary cells, measured by an 
increase in fluorescence, together with the intensity ratio of orange J-aggregates to green 
monomers were used to monitor the mitochondrial membrane potential change induced during 
estrogen-induced pituitary tumoral development. CCCP (0.5 µl/ Stock solution 50 µM) and H2O2 
(2.5 µl/ Stock solution 100 µM) were used as positive controls for membrane polarity and for 
stimulating ROS production, respectively. 
 
2.15 Measurement of the respiratory chain enzyme activities 
Complex I activity was measured by the rate of NADH-dependent ferricyanide reduction at 420 nm 
(1 mM−1cm−1) [45] with the cytochrome c oxidase activity (complex IV) being also determined 
spectrophotometrically measuring cytochrome c oxidation at 550 nm [46, 47]. The above-
mentioned methods were slightly modified, as detailed in a previous report [48]. The activities of 
the respiratory chain complexes were calculated as nmol/min -1/mg protein, and measured using a 
temperature-controlled Varian Cary 50 spectrophotometer (Varian, Inc., Palo Alto, CA, USA). 
 
2.16 Reduced Glutathione Determination 
Reduced Glutathione levels were measured according to Browne and Armstrong [49] in tissue 
homogenates after protein precipitation with 20 % trichloroacetic acid. Pituitary samples were 
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diluted in 100 mM PBS pH 8, containing 5 mM EDTA, and incubated with Ortho-fhthalaldehyde (1 
mg/ml methanol) at room temperature for 15 min. Fluorescence was measured using 350 nm 
excitation and 420 nm emission in pituitary homogenates from 5 animals for each experimental 
group. A standard curve of reduced glutathione was used for concentration determination, and 
the results were expressed as nmoles GSH/mg of protein. 
 
2.17 Citrate synthase activity 
Citrate synthase (CS) was measured at 410 nm at room temperature as described previously [50]. 
Pituitary homogenates from normal and estrogen-treated animals were incubated in the reaction 
buffer containing 100 mM Tris-HCl pH 8, 0.1 mM acetyl-CoA, 0.2 mM DTNB, and 0.1 (v/v) Triton X-
100. The assay was initiated by the addition of 10 ml of 20 mM oxalacetate and, 10 min later, the 
absorbance was read on amicroplate reader (Bio-Rad, Hercules, CA, U.S.A.). 
 
2.18 Lactate determination 
Normal and estrogen-induced tumoral pituitaries were suspended in 4X volumes of lactate assay 
buffer using a homogenizer sitting on ice, and centrifuged at 13000 g at 4 °C to remove any 
insoluble material. Then, supernatants were collected and endogenous LDH, which could degrade 
lactate, was removed by sample deproteinization using trichloroacetic acid and centrifuged at 
13000 xg at 4 °C. Finally, the pH solution (pH 7.4) was adjusted with 1 M of cold Tris solution (pH 
8.8), and lactate levels were immediately determined using the colorimetric assay LACT2 (Roche 
Diagnostic GmBH, Mannheim, German). To obtain detectable levels of lactate was 0.2 mmol/l and 
also for statistical purposes, the pituitary glands from 4 animals were pooled for each 
experimental condition. In addition, muscle tissue (10 mg) from the same animals was processed 
in parallel and used as an internal control of lactate determination. 
 
2.19 Statistical analysis 
Statistical analysis was carried out using an analysis of variance with Fisher’s post-test (InfoStat 
version 2015; Grupo InfoStat, Facultad de Ciencias Agropecuarias, Universidad Nacional de 
Córdoba, Argentina). The results were given as the means ± SEM, and the data were obtained 
from at least in three replicates measured from three independent experiments. The significance 
levels were chosen at P< 0.05. Graphical design was performed using the Prism 5 software (Graph-




3.1. Modifications in mitochondrial mass, dynamics and morphology emerged during the 
pituitary tumour development. 
Cellular proliferation is an energy-consuming process, making very interesting to 
understand how the mitochondrial function is altered in tumoral growth. Therefore, our interest 
was focused on the evaluation possible mitochondrial adaptations that occur during the estrogen-
induced pituitary tumour development. 
An essential process that modifies the mitochondrial mass is biogenesis, which can adjust 
energy production by synthesis of new organelles and their components. This cellular program is 
stimulated by the enhancement of NRF-1, NRF-2 (nuclear respiratory factors 1 and 2) and TFAM 
(transcription factor A, mitochondrial) transcriptional activity, which are the main factors 
responsible for mitochondrial gene expression [51]. The transcript levels of all of these 
mitochondrial biogenesis promoters were markedly induced and sustained during tumour 
development (Figure 1A-D). In addition, as the mitochondrial number, structure and function are 
continuously modified by functional requirements to adapt to different cell demands, we also 
analysed the ultrastructural mitochondrial features. As shown in Figure 1E, an enlargement in the 
mitochondrial area was detected from the earliest stages of pituitary tumoral development, which 
was also accompanied by a sustained and significant rise in CS activity, as a mitochondrial mass 
marker, with tumour development from 20 to 60 days (Figure 1F). However, the morphometric 
analysis of mitochondria in normal and tumoral pituitaries revealed a slight increase in the number 
of mitochondria per area only for the E10 condition, when examined by TEM (p<0.05 Figure 1G-H).  
Mitochondrial morphology is tightly regulated by the coordination of fusion and fission 
events, so that variations in their balance can cause excessive mitochondrial fragmentation or 
elongation. These processes involve dynamin-related protein 1 (DRP1) and mitochondrial fission 
factors MFF and FIS1, which constitute the core of mitochondrial fission machinery, and the 
dynamin-like GTPases, mitofusin 1 and 2 (MFN 1 and MFN2), and optic atrophy type 1 (OPA1) 
proteins, which mainly regulate mitochondrial fusion processes [52]. Thus, to try to understand 
the mitochondrial dynamics implications, we evaluated the expression of the fusion proteins MFN-
2 and OPA-1 by Western blot (WB). The expression of both proteins was progressively intensified 
during pituitary tumour development (Figure 1I; Suppl Figure 1), in association with a prevalence 
of a circular shape at the expense of a decreased mitochondrial elongation, as detected by 
ultrastructural analysis (p<0,05; Figure 1J-L). We found an increased protein level of DRP-1 
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phosphorilated serine 637 (Figure 1I), indicating the inhibition of mitochondrial fission [53]. These 
results, supported also by our previous findings regarding MFN-1 and DRP-1 proteins suggest an 
imbalance of the protein involved in mitochondrial dynamics, thereby favouring fusion processes 
[17]. 
3.2.  Adaptation of the mitochondrial functionality occurred during experimental pituitary 
tumour development 
It has been frequently supposed that tumoral cells may show defective OXPHOS [54]. 
Thus, we next evaluated the enzymatic activity of complexes I (NADH: ubiquinone oxidoreductase) 
and IV (cytochrome c oxidase), which comprise two complexes of the three energy-conserving 
core of the electron transport chain (ETC). As shown in Figure 2A, the Complex I activity was 
mainly unaltered, showing a rise only at the beginning of tumour progression (E10), in agreement 
with the increased mitochondrial number. In contrast, a marked increase in Complex IV activity 
was detected, starting from E20 and continuing over time (p<0.05; Figure 2B). These results may 
suggest that OXPHOS activity is not compromised during tumour development. 
The enzyme Creatine Kinase (CK) also plays a main role in cellular energy buffering and 
transport, thereby balancing its availability between the cell compartments [55]. The 
determination of CK activity showed a significant increase of its enzyme activity, practically for all 
the pituitary tumour growth periods analysed (Figure 2C). These data may reveal that, despite 
presenting functional ETC complexes as mentioned above, the pituitary tumoral cells may need 
energy buffering between compartments. 
A common feature of tumoral cells is the enhanced rate of glycolysis [56, 57]. As shown in 
Figure 2D, a sustained increment in lactate production was detected during pituitary tumour 
development (p<0.05). The data strongly suggest a shift to a glycolytic metabolism. Furthermore, 
this finding might indicate that glycolysis and OXPHOS are both essential for pituitary tumour 
progression, or also may suggest that glycolysis must provide further advantages, probably  
resulting in rapidly ATP supply or providing carbons for biomass generation [58]. 
 The assessment of the mitochondrial membrane potential (MMP) is also frequently used 
to indicate mitochondrial health, as a sign of proton circuit efficiency in OXPHOS [9]. 
Consequently, we analysed the time-course changes in the red/green fluorescence ratio of the JC-
1 mitoprobe during pituitary tumour development. Significant differences in this ratio were 
detected, showing an increase in the MMP from E40 (Figure 2E), which is consistent with several 
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reports on other tumors [59-63], and may suggest an accumulation of proton force that could 
possibly be related to a detrimental effect on ATP synthesis.  
3.3. ROS production and oxidative damage in pituitary tumour development 
Through different approaches we analysed the oxidative stress status during the pituitary 
tumour development. As shown in Figure 3A, the cellular ROS levels progressively increased from 
E20, reaching a 2 fold increase at the E60 endpoint. ROS can harm almost all classes of subcellular 
components, so we investigated whether the higher ROS production detected under our 
experimental conditions was accompanied by oxidative damage of relevant biomolecules. With 
regard to proteins, carbonylation is considered to be the main modification occurring after severe 
oxidative damage [64] and, as shown in Figure 3B, a notable increase in the amount of carbonyl 
groups was detected from the early stages of tumoral progression (E10-E20), with values attaining 
a 3 fold increase compared to basal pituitaries. Interestingly, these protein damage signals were 
not sustained until the last stages evaluated, as a recovery in the basal values was detected (Figure 
3B). 
Another relevant biomolecule susceptible to oxidative damage is DNA. Hence, we initially 
evaluated p-γH2AX protein expression as a hallmark of DNA damage, which demonstrated gradual 
increases from the start of tumoral development, but recovering to normal levels at E60 (Figure 
3C; Suppl Fig 2). Concerning ROS damage to DNA, 8-OHG is one of the most common markers used 
for the evaluation of oxidative DNA lesions [65]. Therefore, we detected a striking increase 8-OHG 
protein expression levels by WB from the early stages of pituitary tumour development (Figure 3C; 
Suppl Fig 2). This result was also supported by immunohistochemistry, as a noticeable rise was 
recorded in the amount of pituitary cells displaying an augmented nuclear 8-OHG protein level 
(Figure 3D). Moreover, this assay also revealed relevant cytoplasmic 8-OHG protein localization, 
probably indicating oxidized mitochondrial DNA. 
 In the context genetic integrity, the enzyme 8-Oxoguanine DNA glycosylase/AP lyase 1 
(OGG-1) plays an important role in protection against cellular damage by ROS [66]. Consequently, 
a significant rise in mRNA OGG1 levels was detected from E10 (Figure 3E), indicating the activation 
of oxidative repair responses during the development of pituitary tumours. 
The maintenance of a cell proliferation rhythm and cell survival depends on the redox 
homeostasis between ROS production and elimination [67]. In fact, cells have a variety of 
antioxidant defense systems, with one of the most common being glutathione, which acts as 
central sensor of oxidative stress and is considered to be the major non-enzymatic antioxidant 
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[68]. The determination of the quantity of glutathione revealed a significant decrease in its 
availability from E10 to E40, although basal values gradually recovered by E60 (Figure 3F). These 
data may show an increased glutathione detoxification activity, yet also with a decreased capacity 
in order to replenish the glutathione pool that usually maintains the reducing cycle. 
3.4.  Oxidative stress response is activated in pituitary tumour cells 
Several of the above-mentioned oxidative damage kinetics returned to basal values, 
suggesting the re-establishment of healthy biomolecules levels and an antioxidant system at E60, 
indicating the activation of a cellular detoxification signalling pathway as a response to oxidative 
injuries. In this regard, the transcription factor Nrf-2, is a master regulator of the cellular response 
under oxidative agents and has a coordinator role in the regulation of redox balance [16]. 
Subsequent to our observations related to the oxidative stress in the pituitary tumour, we 
evaluated the total and phosphorylated Nrf-2 (p-Nrf-2) protein expression levels in nuclear 
fractions from normal and tumoral pituitary glands. It can be observed in Figure 3G that a gradual 
increase in both protein levels was detected during the pituitary tumour growth (p<0.05; Suppl Fig 
2), with this response also being accompanied by a significant rise in mRNA Nrf2 levels starting 
from E10 up to E40 (p<0.05, Figure 3H). Additionally, we evaluated the expression of an Nrf-2 
downstream effector, the oxidative stress-associated HO-1, which revealed increases at E10 and 
E60 (Figure 3I; Suppl Fig 2). These findings showed a clear activation of the oxidative stress 
response during pituitary tumour development, probably leading to the extensive surviving 
capabilities of pituitary cells.  
3.5.  Hypermethylation of the p53 promoter accompanied energetic and metabolic shifts in 
pituitary tumours 
Epigenetic control of nuclear gene expression is highly sensitive to the mitochondrial 
function [69, 70]. Therefore, an intriguing question was whether metabolism alteration in the 
pituitary gland could be accompanied by changes in the epigenetic status. Thus, to assess whether 
cellular adaptation during pituitary tumour development also involved epigenetic modifications, 
we initially compared global DNA methylation profiles during pituitary tumour development. By 
restriction endonuclease digestion of DNA pituitary extracts, a decrease was observed in the 
overall DNA methylation during tumour progression (Figure 4A-B). Then, a decrease in the protein 
expression levels of DNMT1 (DNA methyltransferase 1) was detected from E20 (Figure 4C-D), 
together with a reduction in its levels of mRNA in E60 (Figure 4E-F) 
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Hypomethylation is a common feature of the tumorogenesis epigenome. However, it also 
frequently harbours hypermethylation of specific tumour growth regulator promoters [71, 72]. 
Several genes linked to the most important tumour suppressors Rb and p53 were previously found 
to have been inactivated in pituitary tumours by epigenetic mechanisms [73-75]. In this regard, 
p53 is a relevant transcription factor that also regulates a metabolic rewiring in order to suppress 
proliferation pathways of stressed or damaged cells, suggesting that p53 may contribute to global 
metabolic functions distinct from its well-characterized responses to specific cellular stresses [76, 
77]. Through the evaluation of the TP53 promoter methylation status, we detected significant 
signs of hypermethylation (Figure 4H) accompanied by a gradual restoration of mRNA p53 basal 
levels during tumoral progression (Figure 4I). These results may indicate that a progressive 
expression loss can be sustained by epigenetic modification in order to help maintain a metabolic 




A deep understanding of how mitochondrial alterations contribute to cell growth and 
tumorigenesis is an underexplored research area beyond Warburg effect, regarding its significance 
in tumoral development behaviour. We have previously described that experimental pituitary 
tumours are characterized by a benign growth which involves, in addition to proliferation, an 
increased cellular senescence as evidence of a cell arrest mechanism together with no apoptosis 
signs [17]. In this context, it is important to mention that despite the large number of metabolic 
aberrations thus far identified for tumorigenesis, apparently none of these is common to all 
tumour types. Hence, to have a clear understanding of the physiological basis of pituitary 
adenoma pathogenesis, we studied several aspects of mitochondrial morphology and energy 
metabolism through different approaches during the in vivo development of experimental 
pituitary tumours. It was found that pituitary cells showed clear evidence of oxidative stress in 
association with oxidative damage, accompanied by bigger and round mitochondria probably 
related to an increased fusion process and augmented biogenesis. These events took place in 
unison with an important Nrf2 stress response pathway activation, which may have led to the 
attenuated oxidative damage found during tumour development, providing survival advantages to 
pituitary cells. These neoplasms also presented a progressive increase in lactate production, 
suggesting a metabolic shift towards glycolysis. Furthermore, data obtained from epigenetic 
analysis might suggest that pituitary neoplasm harbours features of the cancer epigenome, due to 
a global hypomethylation and focal hypermethylation of p53. We envisage that these data may 
reflect pituitary cell metabolism regulation by adapting to different energy requirements and 
signalling events in a pathophysiological situation in order to obtain protection from damage and 
to enhance survival chances. We propose that the mitochondria function and oxidative stress or 
damage might play critical a role in pituitary tumour progression, thus targeting mitochondrial 
alterations and signalling could be a promising strategy for the development of selective anti-
tumoral therapy in the case of endocrine tumours. 
Distinct subpopulations of cancer cells coexist in tumours and contribute to functional 
heterogeneity. Each subpopulation seems to rely on different metabolic programs to maintain 
their energy. In experimental pituitary tumours, the coexistence of proliferative events together 
with the activation of growth control mechanisms may surely result in a particular combination of 
cell signalling pathways. As a greater amount of energy must be needed to carry out the initial 
burst observed in pituitary tumour proliferation [17], this might explain the increase in 
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mitochondrial mass, biogenesis and ETC complex functionality [78]. In addition, the rapid 
production of ATP by glycolysis may be an optimal energy source in the growing context [57]. 
However, our present results also revealed an important oxidative stress effect with a 
concomitant oxidative damage induction during pituitary tumour development. Whereas it is 
known that excessive damage accumulation can lead to cell death [79], during pituitary tumour 
development a relevant increase in the Nrf2 detoxification pathway was seen in the current study. 
Hence, it is possible that attenuation of damage could contribute to the survival of pituitary cells 
[80, 81], thereby requiring an alternative energetic metabolism that may even support the 
senescent cellular arrest we have previously described [17].  
The extent to which the control of dynamics, mass and subcellular spatial mitochondrial 
organization is deregulated has been less explored than other mitochondrial aspects in 
tumorigenesis [10]. Also, the mitochondrial structure alterations are heterogeneous and not 
specific to any neoplasm or microenvironment conditions, even more research about 
mitochondrial mass in primary tumours in vivo is scarce. Here, a rise in energetic demand due to 
proliferative stimulus, and also the possibility of mitochondrial damage may explain the increase in 
biogenesis [82, 83] in association with the augmented mitochondrial mass revealed by the CS 
analysis during pituitary tumour progression. Despite the increased mitochondrial biogenesis and 
mass, there was only a slight increase in the mitochondria number. Concomitantly, a gradual 
promotion of the mitochondrial fusion process was detected, suggesting that new mass may 
constantly be incorporated by fusion during tumour development, implying modifications 
reflected in bigger and rounded mitochondria as the pituitary tumour developed, as was also 
reported by others authors [28, 29, 31].  
Whereas mitochondrial fission permits renewal and redistribution inside the cells [84, 85]; 
fusion allows cell interaction and communication. In addition, fusion has also been associated with 
higher a mitochondrial efficiency [86, 87] since it may promote more a rapid diffusion of the 
matrix metabolites required to drive more efficient OXPHOS and also stimulate complementation 
of mtDNA mutations [88]. Additionally, the so-called “stress-induced mitochondrial hyperfusion” 
[89, 90] may also prevent the mitochondrial fragmentation and dismantling of the mitochondrial 
network, which sensitizes cells to death via apoptosis [89, 91] as a response to damage. Since an 
enduring overall shift toward fusion events may lead to the establishment of arrested cellular 
senescent cells [92], therefore, from a functional standpoint, we believe that -in pituitary tumours- 
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a profuse and long-term mitochondrial fusion might promote survival of this master gland by 
avoiding dysfunctions in injured mitochondria while preserving a suitable bioenergetic capacity. 
The tumour cell metabolism also differs from that of normal cells, but a comprehensive 
examination of the metabolic status of pituitary tumours has not yet been performed. Here, we 
demonstrated that pituitary tumours had functional ETC activity, yet displayed a progressive 
increased in the glycolysis rate compared with normal cells. In particular, glycolysis seems to be 
the main energy pathway involved in slow-growing solid tumours [93, 94]. The Warburg effect is 
considered to be a mandatory metabolic change that allows cells to divide and proliferate [12], 
which sustains growth rates through rapidly increasing ATP levels and supports biomass 
generation [58, 95]. Thus, the progressive rise in lactate production may provide carbons to 
generate biomass [57], since we have already reported that pituitary tumour cells become 
hypertrophic and covered with organelles engaged in protein synthesis [96]. In this regard, it has 
been reported that the majority of untreated pituitary tumours have an increased HIF- 1α 
expression [97], which could be related with the expression of glycolytic genes [98], and also 
linked to decreased p53 [76]. 
Defects in mitochondrial respiration are not necessarily the cause of tumour glycolysis, as 
it has been reported that OXPHOS is not impaired in most tumoral cells [99-101]. Thus, a more 
extensive analysis of either energy production or consumption and substrate preferences needs to 
be performed to determine whether mitochondrial respiration is defective in pituitary cells. 
However, in our study, these cells seemed to be quite active as both I and IV complex activities 
rose during pituitary tumor growth, which we interpreted as a functional MRC state. The increase 
in complex I activity, particularly at E10, might be mainly associated with a first line of response to 
a bigger energy demand, together with an elevation in the mitochondrial number.    
Considering MRC efficiency, complex IV has been suggested to be a major regulation site 
for oxidative phosphorylation [102] Hence, the higher complex IV activity demonstrated here may 
support our suggestion of an active respiration rate in pituitary tumors. However, it has been 
reported that at high intramitochondrial ATP/ADP ratios can inhibit cytochrome c oxidase [103]. 
Thus, even when MRC substrates continue to be oxidized, this does not imply a concomitant ATP 
production. Several studies have suggested that enhancing respiratory rates without ATP synthesis 
is advantageous under some conditions [104-107].  
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The inhibition of proton flux through ATP synthase may lead to an increase in MMP. Those 
increased complex IV activity might suggest the existence of functional MRC pumping protons into 
the interspace membrane, thereby contributing to maintain elevated MMP hyperpolarized 
organelles, rather than causing depolarization and possibly leading to apoptosis. In the present 
work, we noted a gradual increase in MMP polarization in pituitary cells during tumoral 
development, in agreement with other reports for different tumours [59-63, 108-110], and this 
alteration may result in a sub-optimal value for ATP production [111]. In this context, we propose 
that sustained growth rates and ATP levels during pituitary tumor growth could be preferentially 
attributable to a concurrent increase in glycolysis [57] and CK buffer activity [55, 112] , while 
pituitary tumors may accumulate damaged or defective mitochondria. Consequently, we believe 
that the mitochondrial integrity in pituitary tumors might be in part a consequence of the balance 
toward mitochondrial fusion processes, which are probably will be coupled with the 
hyperpolarized MMP when chronic damage could be attained at E40 and E60. 
It is probable that tumoral cells do not use aerobic respiration and MMP in the same way 
as normal cells. In fact, MMP maintenance is particularly significant for mitochondrial health, 
because depolarized potentials could lead to apoptosis and avoiding cell death is a central tumour 
ability acquisition [113, 114]. As we have previously reported that pituitary tumours exhibited 
almost null apoptotic figures [17], it is possible to argue that maintaining hyperpolarised MMP 
[113, 115, 116]; which is also related to the increased mitochondrial size detected [117] or 
elevated fusion [118, 119], might help prevent cell death Consequently, the increased MMP 
polarization in pituitary tumours above mentioned could be the outcome response of a 
conjunction of some of the respiration mechanisms that might confer selective survival advantage 
in addition to rapid ATP generation. Conversely, this choice may also lead to an increase in ROS 
production, but the activation of the Nrf-2 antioxidant pathway detected in our study, would make 
the pituitary tumour cells more tolerant to oxidative stress [120]. Summing up, we postulate that 
sustained changes in tumour cellular bioenergetics together with the damage accumulation 
detected during tumoral progression, lead to a metabolic reprogramming in the pituitary gland, 
with stronger adaptive responses that seemingly work as a survival program. Nevertheless, further 
analysis must be carried out to elucidate if the MRC is working properly and whether the rate of 
ATP is accurate. 
ROS can contribute to mitochondrial signalling in cell growth, cellular senescence and 
differentiation [121]. However, ROS may also have a causative role in the progression of 
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tumourigenesis [15, 122, 123], as they increase under tumoral contexts [124, 125]. In agreement, 
in this investigation, a progressive rise in ROS production was detected during pituitary tumour 
development, which may have been primarily derived from mitochondria [14]; although 
ineffectiveness in ETC, greater metabolic demand, incomplete ROS scavenging, replicative stress 
and affected mitochondrial dynamics cannot be discarded [121, 126, 127]. 
In the present work, we detected clear signs of oxidative damage in different 
biomolecules. Among these, we showed an increased protein oxidative damage, DNA damage 
signals and an augmented oxidized DNA during pituitary tumour development, which could imply 
important mutagenic lesions and can cause genomic instability [65, 128]. Also, the 8OH-dG 
cytoplasmic signs of DNA damage detected suggest that mtDNA, whose vulnerability is prone to 
proto-oncogenic mutations [129], may be compromised in pituitary tumours. In particular, 
oxidative damage was detected earlier in proteins and DNA than the increase in ROS levels. A 
plausible explanation for this could be that additional sources of reactive species, not specifically 
those detected by DCF, inflict oxidative damage to biomolecules from the start of tumour 
induction [130]. 
 We speculate that the oxidative damage detected throughout pituitary tumoral 
development sets the platform for early cell transformation in these adenomas, and at the same 
time may contribute to triggering the growth arrest through cellular senescence [131, 132], 
thereby setting a status of oxidative stress that may have an impact on the pathogenesis of 
pituitary tumorigenesis. 
Redox homeostasis is a central process for cell survival and antioxidant enzymes have 
been shown to have altered levels in tumours, with most of these found to be deficient [133, 134]. 
Under the present experimental conditions, the decrease in GSH levels during the initial days of 
tumour progression suggests that the GSH pool might not be replenished concomitantly, which 
may also be an additional signal of oxidative stress [68]. However, the GSH levels were in fact 
gradually restored by the end of tumoral progression in our model.  
GSH production is supported by Nrf2 expression through the control of GSH synthesis 
[135]. Remarkably, we observed a solid trigger of Nrf2 expression and activation with an up-
regulated expression of stress response genes, such as HO-1 [136]. This Nrf2 pathway stimulation 
might be a response to oxidative insults and may support cellular detoxification through metabolic 
rewiring to sustain the antioxidant systems in pituitary tumorigenesis. An oxidative damage 
24 
 
restoration kinetic during pituitary tumour development has been seen in protein damage, also 
connected with Nrf2 activity, as it enhanced the recognition, repair, and removal of damaged 
proteins [137]. In parallel, we detected an increased expression of the repair enzyme OGG1 
involved in the removal of 8-OHG from DNA [138] from the beginning of tumour development. As 
OGG1 expression is also susceptible to Nrf2 activation [139], Nrf2 may influence the pituitary cells 
fate by guiding them into antioxidant response pathways for the replacement and repair of 
damaged components. 
It is intriguing how cells can balance the requirements of growth and homeostasis, with 
the redox balance strongly influencing cell proliferation rhythm [67]. Many Nrf2-regulated 
metabolic pathways confer growth advantages to tumour cells [137, 140] and constitutive 
activation of the Nrf2 pathway has been detected in human tumours [141, 142]. This activation is 
associated with a poor prognosis [143] and has also been considered to be a resistance 
mechanism to chemo- or radiation therapy because it eliminates therapy-induced ROS, thereby 
promoting cell survival [144]. In the present study, we observed that the main signs of oxidative 
damage appeared during the first 10 days of tumoral induction. Then, the restoration kinetics 
observed suggest that after 20 days the cells might undergo a detoxification response, probably 
through a readjustment of their metabolism. The Nrf2-mediated antioxidant response activation 
during the progression of pituitary tumour development can result in damage alleviation which 
might help to confer pituitary cells a non-lethal condition that may, at least in part, explain the 
decrease in proliferation and upsurge of cellular senescence [141].  
Despite activation of the Nrf2 stress response pathway, the ROS levels in pituitary tumors 
still increased even at E60. However, the fact that ROS tends to accumulate during pituitary 
tumour development, does not necessarily imply any further oxidative damage, as defences 
systems may not have been overcome [120]. As ROS are needed for signalling [120] for example 
they can mediate Nrf2 stabilization [145] , an emerging model is proposed that tumoral cells raise 
the production of ROS to trigger localized pro-tumorigenic signalling, but stabilize the increased 
ROS with a higher antioxidant activity to preserve the redox balance [120]. In this regard, ROS level 
detection and oxidative damage during pituitary tumour growth may not have a linear correlation. 
Instead, the relative contribution of the antioxidant equipment and the rate of removal of ROS 
may also need to be taken into account [146-148]. Hence, the antioxidant response resulting from 
Nrf2 activation in pituitary tumours could be considered to be a relevant event that may 
contribute to the slow and benign characteristics of pituitary neoplastic growth. 
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Tumor suppressor p53 is able to regulate certain metabolic pathways, promoting 
respiration while constraining glycolysis in order to achieve tumour growth prevention [76]. Thus, 
the glycolysis rise detected in pituitary tumours might be promoted by a loss of p53 function due 
to the gradual reversion to mRNA p53 basal levels observed after E10 in the present work, in 
agreement with data we have previously reported for p53 protein expression [17]. Related to this, 
we also have previously suggested that an increased activity of p53 at the beginning of 
experimental pituitary tumour development may be associated with the cellular senescence arrest 
trigger, which reduces afterwards to be replaced by p21 accumulation, as previously proposed by 
others [149]. Concomitantly, a detoxification process may appear as new requirement for survival.  
Interestingly, when p53 is strongly up-regulated, the antioxidant response genes are 
down-regulated [150]. Hence, the weak p53 induction observed in the present work might result 
in Nrf2 stabilization by p21, thus arresting the cell [151] and allowing the induction of DNA 
damage-repair and an attempt to lower intracellular ROS, leading to a general cytoprotective 
response [152, 153]. Previously, we have described an accumulation of p21 expression occurring 
together with growth deceleration during pituitary tumour development, which -in this context- 
could also be related to the Nrf2 antioxidant response. It is possible that critical cross-talk 
interactions between Nrf2 and the inhibition of proliferation induced by oxidative-stresmay occur 
during pituitary tumour development [150]. These results suggest that these adaptation 
mechanisms during tumorigenesis may not be limited to alterations in enzyme activity, but also 
involve gene expression regulation [154]. This discovery contributes significantly to an emerging 
network of signalling between p53 and Nfr2, and supports the idea that pituitary tumour cells may 
have a low p53 activity that promotes redox homeostasis, repair and cell survival [155]. 
Mitochondrial function and metabolism affect gene expression by epigenetic regulation 
[69, 70]. Studies have demonstrated that epigenetic alterations are another force affecting the 
expression of genes implicated in neoplastic development [156, 157], thereby comprising pituitary 
tumorigenesis [74, 75, 158]. Here, we found a global hypomethylation of DNA probably due to a 
deregulation of DMNT 1, suggesting a methylation loss by a passive mechanism during pituitary 
tumour progression [159]. In addition, as previously suggested by Pease, Ling, Mack, Wang and 
Zada [73], we detected an increased TP53 promoter methylation in pituitary tumours, which might 
be associated with p53 mRNA regulation as described. These results may imply that pituitary 
neoplasm harbours features of the cancer epigenome which might present global 
hypomethylation and focal hypermethylation [160, 161]. However, this regulation mechanism is 
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not a simple on-off switch, but rather responds in a continuous manner to the changing metabolic 
needs of the cell. Hopefully, our pituitary tumour development model might permit us to reach 
conclusions about time-lapse regulation and switches. Although the functional consequences of 
this epigenetic modification are unclear, we propose that via epigenetic adjustment, pituitary cells 
could maintain a new metabolic state and thus favour cell survival even in the presence of a 




In summary, our data suggest that the mitochondrial metabolism plasticity that takes 
place in pituitary tumours leads to an improved fitness of the resulting cells in order to cope with 
the damage in the context of tumoral development. The metabolic shift might be an important 
mechanism to support the remarkable ‘‘growth advantage’’ that a tumour cell needs to overgrow 
its contemporaries which favours cells that have increased resistance to the disadvantageous 
oxidative microenvironment. 
From the collective data presented, we propose that cooperative actions of p53 and Nrf2 
might lead to cell repair and evasion of apoptosis during pituitary tumour development. Certain 
gene features may alter a set of different signalling pathways alone or in conjunction with each 
other, leading to pituitary tumoral cells exhibiting redox homeostasis restoration in an attempt to 
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LEGENDS OF FIGURES  
Figure 1. Alterations in mitochondrial features in experimental pituitary tumours  
(A-D) Representative image of NRF1, NRF2 and TFAM RNA relative expression during tumoral 
pituitary development determined by RT-PCR. (E) Mitochondrial size by TEM. (F) Citrate synthase 
content determined by absorbance from control and estrogen-treated animals. (G) Mitochondrial 
morphometry by TEM. (H) Representative electron micrographs of normal and tumoral pituitary 
glands (E10): symbols highlight the mitochondria present in the area. (I) Fission (p-DRP1) and 
fusion (MFN2 and OPA-1) protein expression from cytosolic extracts of control and tumoral glands. 
(J) Mitochondrial circularity by TEM. (K) Representative electron micrographs from normal and 
tumoral pituitaries depicting mitochondrial morphological alterations after 60 days of estrogen 
stimulation. (L) Mitochondrial elongation from control and estrogen-treated animals. The β-actin 
mRNA and -tubulin protein expression confirmed that equal loading occurred in all lanes. Data 
are from a representative experiment from a total of three independent experiments with similar 
results. Values are expressed as mean ± SEM. p<0.05, *vs Basal. ANOVA followed Fischer post hoc 
test. Scale bar: 2 µm. 
Figure 2. Modification in mitochondrial functionality during pituitary tumours. 
(A-B) Respiratory chain complexes I and IV enzymatic activity during pituitary tumoral 
development. (C) CK levels from control and estrogen-induced pituitary tumors assessed by a 
colorimetric assay. (D) Lactate concentration from control and tumoral pituitaries analysed by a 
colorimetric assay; skeletal muscle was used as positive control. (E) Mitochondrial membrane 
potential determined by JC-1 assay in pituitary cells during estrogen-induced tumoral 
development. CCCP (carbonyl cyanide 3-chlorophenylhydrazone) was used as positive control. 
Values are expressed as mean ± SEM. p<0.05, *vs Basal, ANOVA followed Fischer post hoc test. 
Figure 3. Signs of oxidative stress and DNA oxidation in pituitary tumours. 
(A) Reactive species production in normal and tumoral pituitary cells; H2O2 was used as positive 
control. Data are expressed as percentage of control. (B) The oxidative damage to proteins was 
measured by quantifying carbonyl groups during tumoral development. (C) 8OHdG and p-γH2AX 
protein expression levels in nuclear extracts from normal and tumoral pituitaries. (D) Paraffin 
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embedded adenohypophysis sections depicting nuclear 8OHdG immunocytochemical detection in 
control and tumoral pituitaries (E10 and E60). (E) OGG1 mRNA expression levels and (F) Reduced 
glutathione expression from control and tumoral pituitary cells determined by a colorimetric 
assay. (G) Nrf2 and p-Nrf2 protein expression from nuclear fractions determined by WB. (H) Nrf2 
RNAm expression levels during estrogen-induced pituitary tumour development. (I) HO-1 protein 
expression from cytosolic extracts evaluated by WB. The β-actin mRNA and -tubulin and Lamin B 
protein expression confirmed equal loading occurring in all lanes. Images correspond to a 
representative experiment from a total of three with similar results. Values are expressed as mean 
± SEM. p<0.05, * vs Basal, ANOVA followed Fischer post hoc test. Scale bar: 20 µm. 
 
Figure 4: Analysis of global DNA and p53 gene promoter methylation during experimental 
pituitary tumour development. 
(A-B) Representative electrophoresis and densitometric analysis of non-undigested DNA (-), MspI- 
and HpaII-digested DNA samples are shown. (C-D) Representative image and analysis of DNMT1 
protein expression during pituitary tumoral development are shown. (E) Representative 
electrophoresis of DNMTs (1, 3A and 3B) and TET (1, 2, 3) mRNA expression levels evaluated by 
RT-PCR is presented. (F) Densitometric analysis of DNMT1/β-actin mRNA ratio. (G) DNMT1 
subcellular localization in normal and tumoral cells. DNMT1 immunolabeling depicts a punctuate 
staining at nuclear level (arrowheads) with a diffuse cytosolic staining in basal and at E10. A lack of 
DNMT1 nuclear localization was observed at E60. (H) Representative electrophoresis and 
densitometric analysis of TP53 gene promoter methylation is shown. The (–) symbol indicates 
undigested DNA samples and (+) HpaII-digested DNA samples. (I) Representative image and 
densitometric analysis of p53/β-actin mRNA ratio determined by RT-PCR. Data are expressed as 
mean ± SEM. * p<0.05 vs Basal, ANOVA followed by Fischer post hoc test. Bar: 10µm. 
Supplemental Figure 1: Mitochondrial dynamic protein expression during experimental pituitary 
tumour development 
(A-B-C) Representative images and densitometric analysis of OPA-1, MFN-2 and p-DRP1/α tubulin 
ratio, determined by WB. Data are expressed as mean ± SEM. * p<0.05 vs Basal, ANOVA followed 
by Fischer post hoc test. 
Supplemental Figure 2: Oxidative stress and DNA damage markers in pituitary tumours. (A-B-C-
D-E) Representative images and densitometric analysis of 8OHdG, p-H2AX, Nrf2, p-Nrf2 and HO-
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1/Lam B ratio, determined by WB. Data are expressed as mean ± SEM. * p<0.05 vs Basal, ANOVA 
followed by Fischer post hoc test. 
 
Table 1: Primer sequences for gene expression and promoter methylation analysis 
Gene Accession No. Note Sequence (5' to 3') Amplicon (bp) 
NRF1 NM_001100708.1 Gene expression  
(F) ACG ATG GGC GGG AGG ACC TT 
500 
(R) TCC AAC GGC TGC TGC GGT TT 
NRF2 NC_005110.4  Gene expression  
(F) TAA GCC AGG CCA TAG ACA TC 
292 
(R) CGA GGA ACC CCC TGA AA 
TFAM NM_031326.1 Gene expression  
(F) AAA TGG CTG AAG TTG TTC TAAT TG 
120 
(R) AGC TTC TTG GTG CCC AAT CCC AATG 
OGG1 NC_005103.4 Gene expression  
(F) CTA AGA AGA CAG AAG GCT AGG TAG 
210 
(R) TGA CTT TGA TTT GGG ATG TTT GC 
Nrf2 NM_031789.2 Gene expression  
(F) CAG TCT TCA CCA CCC CTG AT 
100 
(R) CCA AAC TTG CTC CAT GTC CT 
DNMT1 NM_053354.3  Gene expression  
(F) AGG ACC CAG ACA GAG AAG CA 
240 
(R) GTA CGG GAA TGC TGA GTG GT 
DNMT3A NM_001003958.1  Gene expression  
(F) AGG AAG CCC ATC CGG GTG CTA 
88 
(R) AGC GGT CCA CTT GGA TGC CC 
DNMT3B NM_001003959.1  Gene expression  
(F) GTG AAG CGG ATG ATG GAG AT 
230 
(R) CCT CCG AGA CTT GGT AGC TG 
TET 1 XM_006223880.2 Gene expression  
(F) TGT CAC CTG TTG CAT GGA TTT   
208 
(R) TTG GAT CTT GGC TTT CAT CC 
TET 2  XM_006224264.2 Gene expression  
(F) AAT CGC CTT CGG ATT CAG ACA CTC 
370 
(R) CTT GAC CTC CGA TAC ACC CAT TTA GC 
TET 3  XM_006236793.2 Gene expression  
(F) TGG CTG CAG ACT TGA TCT TCC 
210 
(R) ACC CGG CTC TAT GAA ACC TT 
p53 NM_030989.3 Gene expression  
(F) CTT CGA GAT GTT CCG AGA GC 
100 
(R) CTT CGG GTA GCT GGA GTG AG 
β-actin NM_031144 Gene expression  
(F) ACC CAC ACT GTG CCC ATC TA 
200 
(R) CGG AAC CGC TCA TTG CC 
TP53 NC_005109.4 
Promoter  (F) CGT AGC TCC TCC GAC GTC TT 
200 
methylation analysis (R) GCG AGC CTA TCG GAA GGT G 
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